Comparison of Internal Dosimetry of 18F-PSMA-1007 and 68Ga-PSMA-11-HBED-CC
Conclusion
Whole-body effective dose from 18F-PSMA-1007 is higher compared with 68Ga-PSMA-11-HBED-CC. 18F-PSMA-1007 shows lesser urinary bladder clearance compared with 68Ga-PSMA-11-HBED-CC, which can allow better interpretation of prostatic bed without significant radioactive urine interference. 18F-PSMA-1007 is a cyclotron-produced alternative to generator-produced 68Ga-PSMA-11-HBED-CC and can emerge as a good diagnostic surrogate for patients planned for 177Lu-PSMA-617 therapy.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Original Articles Source Type: research
More News: Bladder Cancer | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cardiology | Gallbladder Cancer | Heart | Liver | Neurology | Nuclear Medicine | Pancreas | Pancreatic Cancer | Prostate Cancer | Study | Urology & Nephrology